Introduction
============

Hyperplasia of mammary gland (HMG), a common disease, occurs among middle-aged women with high frequency ([@B22]). It is a kind of pathological hyperplasia of lobules of mammary gland induced by the disorder of estrogen and progesterone ([@B6]; [@B64]). The morbidity of HMG is increasing nowadays with a risk of breast cancer ([@B11]). Tamoxifen is an estrogen antagonist with antiproliferative effects. It has been widely used for breast cancer as well as HMG ([@B14]; [@B25]). However, some women do not tolerate tamoxifen and have a risk of side effects ([@B23]; [@B35]). Therefore, it is important to discovery safer and more effective drugs with minimum side effects for HMG.

Traditional Chinese medicine (TCM) has been frequently used as alternative treatments for various types of diseases. For complicated or multi-factorial diseases, emerging evidence indicates that multiple drugs that have common or different pharmacological targets often display better therapeutic efficacy than a single medication ([@B45]). The formulae with multiple herbs exert therapeutic efficacies through the synergistic effects of their multiple ingredients via multiple targets ([@B8]; [@B46]).

Li-Ru-Kang (LRK) consisted of Ostreae Concha (Ostrea gigas Thunberg.), Cervi Cornu \[Alpinia aquatica (Retz.) Roscoe.\], Polygoni Multiflori Radix \[Polygoni Multiflori (Thunb.) Moldenke.\], Curcumae Radix (Curcuma aromatica Salisb.), Cremastrae Pseudobulbus Pleiones Pseudobulbus \[Cremastra appendiculate (D. Don) Makino.\], Bupleuri Radix (Bupleurum chinense DC.), Prunellae Spica (Prunellae vulgaris L.) and Glycyrrhizae Radix et rhizoma (Glycyrrhizae uralensis Fish. ex DC). LRK is a Chinese preparation formulated through TCM principles of tonifying the kidney, smoothing the liver, dissipating nodule and activating blood circulation. LRK has an overall regulatory effect on HMG. The randomized trials of LRK showed that LRK had favorable effect in the treatment of HMG ([@B43]; [@B26]). Studies showed that LRK could improve the histological lesions in mammary gland, uterus and ovaries ([@B41]). LRK also affects abnormal secretion of sex hormones in model of HMG induced by estradiol benzoate. The serum levels of estradiol (E2) and prolactin (PRL) were decreased and progesterone (P) was increased remarkably by LRK ([@B42]). Our previous study explained the modulatory properties of LRK treatment on HMG using metabolomics and network pharmacology analyses, showed the therapeutic effects of LRK on HMG ([@B55]). However, the biological mechanisms of LRK for HMG are still blur.

Network pharmacology, a technology for system biology study, could clarify the potential mechanisms of complicated ingredients through large data set analysis. In that TCM formula has been thought to be multi-ingredients and multi-targets, network pharmacology is a suitable approach to meeting this challenge and determining the mechanism on LRK for treating HMG ([@B8]; [@B50]; [@B33]).

Therefore, in the present study, network pharmacology approach combined with molecular biology was performed to further investigate the active ingredients and the underlying mechanism of LRK for the treatment of HMG.

Materials and Methods {#s1}
=====================

Database Construction
---------------------

The chemical structures of the compounds in LRK were obtained from TCM Database\@Taiwan (TDT)^[1](#fn01){ref-type="fn"}^ ([@B9]) and Traditional Chinese Medicine Systems Pharmacology (TCMSP) database^[2](#fn02){ref-type="fn"}^. All compounds were selected according to selection criteria \[oral bioavailability (OB) ≥ 30 and drug-likeness (DL) ≥ 0.18\], as suggested by TCMSP ([@B30]). Known compound targets were collected from Herbal Ingredients' Targets Database (HIT)^[3](#fn03){ref-type="fn"}^ ([@B60]), and the putative targets from these were screened out from Therapeutic Targets Database (TTD)^[4](#fn04){ref-type="fn"}^ through structural similarity comparison ([@B12]). Gene and protein targets associated with HMG therapy were collected from the Online Mendelian Inheritance in Man (OMIM)^[5](#fn05){ref-type="fn"}^ database. Other interaction proteins of the aforementioned targets were obtained from Database of Interacting Proteins (DIP)^[6](#fn06){ref-type="fn"}^, and different ID types of the proteins were converted to UniProt IDs.

Network Construction and Analysis
---------------------------------

To provide the scientific and reasonable interpretation of the complex relationships between the compounds and targets associated with HMG, network analysis was carried out. The compound-target-disease network was constructed using candidate compounds, potential targets and HMG significant targets. The network was performed using Cytoscape 3.5.1 software (National Institute of General Medical Sciences, United States). The topological features of each node in the network were calculated by "Degree", "Betweenness centrality", and "Closeness centrality" ("Degree" values twofold greater than the median value of all the network nodes, "Betweenness centrality" and "Closeness centrality" value greater than the median value of all the network nodes) ([@B53]). Targets with higher value were screened as the candidates for HMG.

Plant Material
--------------

LRK consisted of *Ostreae Concha* (*Ostrea gigas* Thunberg.), *Cervi Cornu* \[*Alpinia aquatica* (Retz.) Roscoe.\], *Polygoni Multiflori Radix* \[*Polygoni Multiflori* (Thunb.) Moldenke.\], *Curcumae Radix (Curcuma aromatica* Salisb.), *Cremastrae Pseudobulbus Pleiones Pseudobulbus* \[*Cremastra appendiculate* (D. Don) Makino.\], *Bupleuri Radix (Bupleurum chinense* DC.), *Prunellae Spica (Prunellae vulgaris* L.) and *Glycyrrhizae Radix et rhizoma (Glycyrrhizae uralensis* Fish. ex DC) which were purchased from Heyanling, Co., Ltd. (Beijing, China). The origin and quality of the 8 herbs were identified according to the Chinese Pharmacopeia (2015 Edition). The eight TCMs of LRK were composited with the weight ratio of 30: 12: 12: 10: 10: 9: 9: 6. At first, *Cervi Cornu* slice were smashed into powder. Then it was decocted with appropriate amount of water and kept slightly boiling for 1 h. Next, the filtrate of *Cervi Cornu* was obtained and combined with the rest of TCM proportionally, followed by another 1 h heat extraction with boiled water (1/10, weight/volume) three times. The final yield of powder to raw materials was about 9.2%.

Reagents
--------

The antibodies of phosphorylation-MAPK Family Antibody Sampler Kit used for western blot were purchased from Cell Signaling (United States) (\#9910). And nuclear factor- (NF-)κB (p65) (XCJ36131), cyclooxygenases 2 (COX2) (06416080202), inducible nitric oxide synthase (iNOS) (16716110102), interleukin-1β (IL-1β) (01016051201), tumor necrosis factor α (TNF-α) (60291-1-Ig), estrogen receptor α (ERα) (AF6058), and progesterone receptor (PR) (37917011102) for immunohistochemistry were purchased from Wu han goodbio technology Co., Ltd (China). Antibodies of 8-hydroxy-2′deoxyguanosine (8-OHdG) (GR3173165-3), nitrotyrosine (NT) (GR174728-22), GAPDH (AC001) were purchased from Abcam (the United States).

Animals and Administration
--------------------------

Female SD rats weighting 180--220 g \[license number: SCXK-(A) 2012--0004\] were obtained from the laboratory animal center of the Military Medical Science Academy of the People's Liberation Army (PLA). They were maintained separately at animal experimental center of 302 Hospital of People's Liberation Army (Beijing) with a specific pathogen free (SPF) environment (24°C, 65% humidity, 12 h day/night). The rats were randomly divided into six groups. All rats except for control group were intramuscularly injected with estrogen at a dose of 0.5 mg/kg/d for consecutive 25 days. All rats but control group were intramuscularly injected with progesterone at a dose of 5 mg/kg/d in the following 5 days ([@B54]). LRK (0.056, 0.112, 0.224 g/kg/d for the low, medium and high dose, respectively) and tamoxifen (Yangtze River Pharmaceutical Co., Ltd. 5 mg/kg/d) were dissolved in normal saline and intragastrically administered to rats, respectively, except for control and model group for 30 days. The rats were sacrificed 12 h after the last administration. All animal studies have been approved by the Ethical Committee of 302 Military hospital of China. The blood, mammary gland and uterus were collected. The blood was centrifuged at 3500 rpm for 15 min to separate the serum without hemolysis. Serum and the rest of mammary gland tissue for hematoxylin-eosin staining were stored at -80°C.

Measurement of Body Weight, Nipple Height and Diameter, and Uterus Indexes
--------------------------------------------------------------------------

Body weight, nipple height and diameter of all rats were recorded after administration. Uterus index ([@B54]) was calculated by the following formulae:
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W~uterus~ and W~body~ stand for the average weight of uterus and body weight of rats.

Histopathological Evaluations and Immunohistochemical Observation
-----------------------------------------------------------------

The mammary gland tissues obtained from the experimental rats were fixed in the 10% neutral buffered formalin and then embedded in paraffin. Subsequently, the embedded mammary gland tissues were cut into thin slices and disposed using hematoxylin-eosin (H&E) staining.

Immunohistochemical analysis was performed using deparaffinized mammary sections. The sections were immersed in freshly prepared 2% H~2~O~2~ at room temperature for 25 min and blocked with 5% rabbit serum for 30 min. Then the primary antibody \[NF-κB (p65) (1:100), -COX-2 (1:1000), -TNF-α (1:200), -IL-1β (1:400), -iNOS (1:1000), -NT (1:100), -8-OHdG (1:100), -ERα (1:200), or -PR (1:200)\] was added and incubated at 4°C overnight. After being washed with PBS, the sections were treated with the secondary antibody conjugated with horseradish peroxidase at room temperature for 50 min. Then, they were immersed in diaminobenzidine (DAB) for 3 min. The hematoxylin-stained sections were dehydrated by ethanol. Stained areas of the sections were visualized using an optical microscope at ×200. Image analysis software Image-Pro Plus 6.0 was used to select the yellow area of the immunohistochemical reactant on the image and then the mean integrated optical density (IOD) of these areas was measured.

Western Blot Analysis
---------------------

The mammary expressions of p-P38 p-JNK and p-ERK were evaluated by western blot analysis. Mammary gland tissue of rats was homogenized and subsequently lysed by tissuelyser (Shanghai Jingxin Industrial Development Co., Ltd, Shanghai, China) with RIPA buffer containing a protease inhibitor mixture. The protein was distilled and then centrifugated at 12,000 rpm and 4°C for 10 min to separate debris. Protein concentration was determined using the BCA protein assay kit. Protein samples (25 μg) were separated by SDS-polyacrylamidegel electrophoresis and transferred to a PVDF membrane by electrophoretic transfer. Transferred membranes were blocked for 1 h at room temperature with 2% BSA in Tris-buffered saline containing 0.1% Tween 20 (TBST), and then incubated overnight at 4°C with different primary antibodies \[anti-p-P38 (1:1000), p-JNK (1:1000) and p-ERK (1:1000)\]. After washes with TBST 4 times, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody (1:3000) in TBST with 2.5% nonfat milk for 1 h at room temperature. Western blots were developed on films using the enhanced chemiluminescence technique. Quantification of bands was determined by densitometric analysis using Bio-Rad Quantity One. The data were normalized using GAPDH (1:3000) as an internal control.

Statistical Analysis
--------------------

Data were presented as means ± SD. and were analyzed using the IBM SPSS Statistics 21. Data among groups were analyzed with ANOVA. *P* \< 0.05 and *P* \< 0.01 were considered statistically significant.

Results
=======

Prediction for the Direct Targets of LRK on HMG
-----------------------------------------------

A total of 72 chemical constituents of LRK, 351 drug targets, 213 HMG targets and 358 interacting proteins were obtained from TDT, HIT, TTD, OMIM, and DIP. Then, the ingredients, drug targets, disease targets and interacting proteins were connected for interaction network of "compound-target-disease" construction, which was presented with color-coded nodes (Figure [1A](#F1){ref-type="fig"}). In the network, the yellow squares represented the direct targets which were the common targets of LRK and HMG. The common targets were the key targets for LRK on treating HMG as well as the relatively important targets screened for further research.

![Compound-target-disease network of LRK. **(A)** The main network of "compound-target-disease" of LRK. **(B)** The sub-network with direct targets and the corresponding ingredients. Notes: The red triangles represent active chemical constituents of LRK, the blue dots represent the indirect targets for drugs, the yellow dots represent the targets of the specific disease of HMG, the yellow squares represent the common targets of herbs and HMG, and the purple dots represent the interactional proteins with the targets of HMG and drugs.](fphar-09-01318-g001){#F1}

Subsequently, the topological parameters values of each target in the network including "Degree", "Betweenness centrality", and "Closeness centrality" were analyzed for the important key protein targets and related signaling pathways screening. The results showed that 13 direct targets were selected according to their Degree twice greater than the median (\>14), Betweenness Centrality and Closeness Centrality greater than the median (Betweenness Centrality value \>0.004; Closeness Centrality value \>0.28) (Table [1](#T1){ref-type="table"}). Additionally, COX2 and NF-κB might be the most important targets of LRK on treating HMG due to their highest degree.

###### 

Topological parameters of Li-Ru-Kang (LRK) on HMG obtained from network pharmacology analysis.

  UniProt ID   Direct target              Degree   Betweenness centrality   Closeness centrality
  ------------ -------------------------- -------- ------------------------ ----------------------
  P35354       PTGS2 COX2                 34       0.020                    0.302
  Q04206       RELA NFKB                  28       0.026                    0.303
  P23219       PTGS1 COX1                 27       0.014                    0.301
  P31749       AKT1 PKB, RAC              25       0.032                    0.328
  P00533       EGFR ERBB, ERBB1, HER1     23       0.026                    0.296
  P37231       PPARG NR1C3                22       0.019                    0.327
  P05412       JUN                        22       0.011                    0.309
  P25963       NFKBIA IKBA, MAD3, NFKBI   22       0.017                    0.293
  P09211       GSTP1 FAEES3, GST3         21       0.021                    0.326
  O15111       CHUK IKKA, TCF16           21       0.019                    0.304
  O14920       IKBKB IKKB                 17       0.007                    0.283
  P00441       SOD1                       17       0.015                    0.282
  P15692       VEGFA VEGF                 16       0.011                    0.284

Prediction of Active Ingredients in LRK
---------------------------------------

Furthermore, active ingredients from LRK were explored be network pharmacology prediction. As shown in Figure [1B](#F1){ref-type="fig"}, 24 potential active ingredients directly related to LRK on HMG. According to the OB ≥ 30 and DL ≥ 0.18, 19 active ingredients including saikosaponin c_qt, quercetin, kaempferol, chrysazin, luteolin, beta-sitosterol, isorhamnetin, curcolactone, stigmasterol, 2-methoxy-9,10-dihydrophenanthrene-4,5-diol, areapillin, morin, 3,5,6,7-tetramethoxy-2-(3,4,5-trimethoxyphenyl) chromone, delphinidin, troxerutin, cubebin, α-spinasterol, linoleyl acetate, and vulgaxanthin-I might be responsible for the effect of LRK on HMG, and they were listed in Table [2](#T2){ref-type="table"}.

###### 

Information of active ingredients of LRK and their topological parameters.

  Compounds                                                  Herbs                                                                                                                                PK parameters   Betweenness centrality   Closeness centrality   Degree      
  ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ --------------- ------------------------ ---------------------- ----------- -----
                                                                                                                                                                                                  OB (%)          DL                                                          
  Saikosaponin c_qt                                          *Bupleuri Radix*                                                                                                                     30.5            0.63                     0.1429255              0.3728633   158
  Quercetin                                                  *Prunellae Spica*                                                                                                                    46.43           0.28                     0.1330894              0.3710792   154
  Kaempferol                                                 *Bupleuri Radix*, *Prunellae Spica*                                                                                                  41.88           0.24                     0.0283762              0.311816    63
  Chrysazin                                                  *Polygoni Multiflori Radix*                                                                                                          28.74           0.19                     0.0430047              0.3024919   62
  Luteolin                                                   *Prunellae Spica*                                                                                                                    36.16           0.25                     0.0664633              0.3213628   57
  Beta-sitosterol                                            *Cremastrae Pseudobulbus Pleiones Pseudobulbus Cremastrae Pseudobulbus Pleiones Pseudobulbus*, *Curcumae Radix*, *Prunellae Spica*   36.91           0.75                     0.0080004              0.2876571   38
  Isorhamnetin                                               *Bupleuri Radix*                                                                                                                     49.6            0.31                     0.0217248              0.2926011   37
  Curcolactone                                               *Curcumae Radix*                                                                                                                     51.51           0.2                      0.0473816              0.288728    37
  Stigmasterol                                               *Prunellae Spica*, *Bupleuri Radix*, *Cremastrae Pseudobulbus Pleiones Cremastrae Pseudobulbus Pleiones Pseudobulbus*                43.83           0.76                     0.0054813              0.274641    31
  2-methoxy-9,10-dihydrophenanthrene-4,5-diol                *Cremastrae Pseudobulbus Pleiones Pseudobulbus*                                                                                      44.97           0.18                     0.0094876              0.2827056   30
  Areapillin                                                 *Bupleuri Radix*                                                                                                                     48.96           0.41                     0.0035804              0.2766548   17
  Morin                                                      *Prunellae Spica*                                                                                                                    46.23           0.27                     0.0068017              0.2666157   17
  3,5,6,7-tetramethoxy-2-(3,4,5-trimethoxyphenyl) chromone   *Bupleuri Radix*                                                                                                                     31.97           0.59                     0.0022551              0.2751281   12
  Delphinidin                                                *Prunellae Spica*                                                                                                                    40.63           0.28                     0.0016301              0.2708576   8
  Troxerutin                                                 *Bupleuri Radix*                                                                                                                     31.6            0.28                     3.50E-05               0.2329384   7
  Cubebin                                                    *Bupleuri Radix*                                                                                                                     57.13           0.64                     4.26E-05               0.2329773   5
  α-spinasterol                                              *Bupleuri Radix*                                                                                                                     42.98           0.76                     3.13E-05               0.2601565   4
  Linoleyl acetate                                           *Bupleuri Radix*                                                                                                                     42.1            0.2                      3.13E-05               0.2601565   4
  Vulgaxanthin-I                                             *Prunellae Spica*                                                                                                                    56.14           0.26                     1.33E-05               0.2363298   2

Pathway Analysis of LRK on HMG
------------------------------

The results above showed that 19 active ingredients related to 13 direct targets played the key role of LRK in treating HMG. However, the key pathways still unknown. Therefore, the pathways of the direct target proteins were enriched. The analysis of KEGG pathways indicated that there were five pathways enriched related to HMG, including MAPK signaling pathway, Toll-like receptor signaling pathway, TNF signaling pathway, NOD-like receptor signaling pathway and Chemokine signaling pathway, which were directly involved in inflammation. The proteins like NF-κB (p65), COX2 were involved in major pathways (Table [3](#T3){ref-type="table"}). According to the count of relative targets and the percentage on all pathways, MAPK signaling pathway might play the key role in LRK treating HMG. These results indicated that the protect effect of LRK on HMG might associate to MAPK pathway, regulate NF-κB, anti-inflammatory, and anti-oxidative stress.

###### 

Potential pathways and the target proteins in KEGG analysis.

  Terms                                  Count   \%     *P*-value   Benjamini   Target protein
  -------------------------------------- ------- ------ ----------- ----------- -------------------------------------
  MAPK signaling pathway                 6       46.2   4.20E-05    2.10E-04    NFKB, JUN, AKT1, IKKA, IKKB, EGFR
  TNF signaling pathway                  6       46.2   9.70E-09    5.40E-07    NF-κB, AKT1, IKBA, IKKA, IKKB, COX2
  Toll-like receptor signaling pathway   6       31.2   5.60E-07    5.70E-06    AKT1, IKKB, IKKA, NF-κB, IKBA, JUN
  Chemokine signaling pathway            5       38.5   2.10E-04    7.70E-04    AKT, IKKA, IKKB, NF-κB, IKBA
  NOD-like receptor signaling pathway    4       30.8   1.00E-04    4.70E-04    IKKA, IKKB, NF-κB, IKBA

Therapeutic Effect of LRK on HMG
--------------------------------

In order to assess the therapeutic effect of LRK, the height and diameter of nipples (left 2 and right 2) and uterus index of rats were measured. As shown in Figure [2](#F2){ref-type="fig"}, both of the left and right nipples were markedly decreased by LRK treatment compared to the HMG model group. Similarly, the diameter of nipples (left 2 and right 2) of rat were also significantly decreased compared to the model group (*P* \< 0.01) (Figures [2A,B](#F2){ref-type="fig"}). And the result showed that the effect of LRK is comparable to the tamoxifen treatment. Uterus is the main target organ of estrogen, the high level of exogenous estrogen will induce the obviously increased of uterus index ([@B22]). Thereby, the uterus index was examined. It showed that the uterus index was decreased in a dose-dependent manner by LRK treatment (Figure [2C](#F2){ref-type="fig"}).

![Height and diameter of left and right nipples, uterus index in different group. **(A)** Height of left and right nipples. **(B)** Diameter of left and right nipples. **(C)** Uterus index; *N* = 9; **(D)** The effect of LRK on the pathological features of mammary gland tissues. ^\#\#^*P* \< 0.01 vs. Control group; ^∗∗^*P* \< 0.01 vs. HMG model group.](fphar-09-01318-g002){#F2}

Subsequently, hematoxylin and eosin (H&E) staining was performed to visualized the pathological changes of mammary gland sections. As shown in Figure [2D](#F2){ref-type="fig"}, Estrogen and progesterone stimulation induced severe HMGs in rats, reveled by histological abnormalities, including significant proliferative lesions, mammary ducts ectasia expansion of mammary lumens, significant increase of acinars and lobules. Conversely, the administration of LRK significantly improved the morphological changes of HMGs dose-dependently. Above all, the results indicated the specific therapeutic effect of LRK on HMG.

Effect of LRK on the Expression of Inflammatory Cytokines (COX-2, IL-1β, iNOS, and TNF-α)
-----------------------------------------------------------------------------------------

Previously studies reported that inflammatory cytokines such as COX-2, IL-1β, iNOS, and TNF-α play important role in the development of HMG ([@B58]; [@B11]; [@B19]). IL-1β and TNF-α, pro-inflammatory cytokines, were significantly increased in model group induced by estrogen and progesterone. While, the LRK treatment could notably decrease the expression of TNF-α and IL-1β compared to model group. COX-2 and iNOS, acted as pro-inflammatory enzymes. LRK treatment significantly inhibited the over-expressions of COX-2 and iNOS in rats induced by estrogen and progesterone in a dose-dependent manner (*P* \< 0.01) (Figure [3](#F3){ref-type="fig"}). In summary, the results showed the significant anti-inflammatory effect of LRK.

![The effect of LRK on the expression of TNF-α, IL-1β, COX-2, and iNOS. The integrated optical density of positive expression of **(A)** TNF-α, **(B)** IL-1β, **(C)** COX-2, **(D)** iNOS; *N* = 3; ^\#\#^*P* \< 0.01 vs. Control group; ^∗∗^*P* \< 0.01 vs. HMG model group.](fphar-09-01318-g003){#F3}

Effect of LRK on Oxidative Stress \[8-OHdG and Nitrotyrosine (NT)\]
-------------------------------------------------------------------

As shown in Figure [4](#F4){ref-type="fig"}, there was an obvious oxidative stress injury in model group, reveled by the high expression of 8-OHdG and NT, markers of oxidative stress, compared to the control group. In the LRK groups, the high expression of 8-OHdG and NT were significantly inhibited in a dose-dependent elevation, which indicated the anti-oxidative stress effect of LRK (Figure [4](#F4){ref-type="fig"}).

![The effect of LRK on the expression of NT and 8-OHdG. The integrated optical density of positive expression of **(A)** NT, **(B)** 8-OHdG in different group; *N* = 3; ^\#\#^*P* \< 0.01 vs. Control group; ^∗∗^*P* \< 0.01 vs. HMG model group.](fphar-09-01318-g004){#F4}

Effect of LRK on Expression of ERα and PR
-----------------------------------------

The expression of estrogen receptor and progesterone receptor in mammary gland plays an important role in the physiological and pathological changes of mammary gland. So, we examined the expression of ERα and PR. As shown in Figure [5](#F5){ref-type="fig"}, LRK could not affect the expression of ERα and PR.

![The effect of LRK on the expression of ERα and PR. The mean optical density of positive expression of **(A)** ERα, **(B)** PR in different groups; *N* = 3.](fphar-09-01318-g005){#F5}

Effect of LRK on Expression of p-JNK, p-P38, p-ERK, and NF-κB (p65)
-------------------------------------------------------------------

The pathway analysis results in this study indicated that LRK may play anti-inflammatory and anti-oxidative stress role through MAPK/ NF-κB signaling pathways. To determine whether LRK could affect MAPK, we examined the expressions of p-JNK, p-P38, p-ERK. The results showed that p-P38, p-ERK, and p-JNK were slightly expressed in normal mammary cells. In HMG model group, expressions of p-P38, p-ERK, and p-JNK were notably increased. LRK administration significantly suppressed the over-expressions of p-P38, p-ERK, and p-JNK versus the model group (Figure [6](#F6){ref-type="fig"}).

![Alterations of the mitogen-activated protein kinase (MAPK) pathways in the mammary glands of LRK-treated rats. **(A)** Expression of p-ERK, p-P38, and p-JNK by western blot analysis; **(B)** The p-ERK/GAPDH ratio; **(C)** the p-P38/GAPDH ratio; **(D)** the p-JNK /GAPDH ratio. Sample loading was normalized by GAPDH. *N* = 3; ^\#\#^*P* \< 0.01 vs. Control group; ^∗∗^*P* \< 0.01 vs. HMG model group.](fphar-09-01318-g006){#F6}

There existed a large degree of cross-talk within the MAPK cascades and other signaling networks. For example, there were interactions between mediators of the MAPK and NF-κB pathway ([@B11]). The expression of NF-κB (p65) was examined by immunohistochemical analysis. NF-κB (p65) was increased significantly in the HMG model group. LRK treatment significantly and dose-dependently suppressed the mammary over-expressions of NF-κB (p65) when compared to the model ones (Figure [7](#F7){ref-type="fig"}).

![The effect of LRK on the expression of NF-κB (p65). Immunohistochemical analysis of NF-κB (p65) in **(A)** Control group, **(B)** HMG Model group, **(C)** H group, **(D)** M group, **(E)** L group, **(F)** The integrated optical density of positive expression of P65; *N* = 3; ^\#\#^*P* \< 0.01 vs. Control group; ^∗∗^*P* \< 0.01 vs. HMG model group.](fphar-09-01318-g007){#F7}

Discussion
==========

HMG, a common disease in middle-aged women has severe cancerous tendencies, and poses a significant public health challenge to women ([@B34]). It is reported that HMG, especially atypical HMG, leads to higher risk of breast cancer. ([@B54]; [@B63]). Studies showed that HMG is related to endocrine disorders, the most of that are caused by the imbalance of estrogen and progestin. ([@B29]; [@B62]) The treatment of HMG has become a heated topic in the world. HMG is mainly treated by surgery and medication ([@B20]; [@B11]). Tamoxifen, as the main therapeutic drug of HMG could improve the overall survival for patients. However, adherence to and persistence with the medications is poor in part because of bothersome side effects that can negatively affect quality of life ([@B20]). Thus, it is important and urgency to find more effective and few side effects drug to block development of HMG.

LRK, a TCM formula, has been clinically used for the treatment of HMG for several years. The First Affiliated Hospital of the General Hospital of PLA conducted clinical trials and demonstrated that LRK could inhibit HMG ([@B26]). Previous study showed high effective rate (88.0%) in the treatment of HMG. Meanwhile the patients' symptoms and abnormalities of gonadal hormone was obvious improved ([@B43]). However, the underlying mechanisms of LRK for HMG are still unclear. Thus, the aim of this study is to explore the underlying mechanism of LRK on HMG.

To clarify the effect of LRK on HMG in rats, we established HMG model in rats induced by estrogen and progesterone. The decreasing of nipple heights and diameters, uterus index and ameliorate of histopathological in LRK groups indicated that LRK could improving HMG in rats. Then, we further explore the active ingredients and underlying mechanism of LRK on HMG.

To reveal the therapeutic mechanisms of LRK on HMG, we firstly predicted the active ingredients and potential targets of LRK against HMG through network pharmacology. We found 19 potential compounds, including saikosaponin c_qt, quercetin, kaempferol and chrysazin, Luteolin, beta-sitosterol, isorhamnetin, curcolactone, stigmasterol, 2-methoxy-9,10-dihydrophenanthrene-4,5-diol, areapillin, morin, 3,5,6,7-tetramethoxy-2-(3,4,5-trimethoxyphenyl) chromone, delphinidin, troxerutin, cubebin, α-spinasterol, linoleyl acetate and vulgaxanthin-I might play the key role in LRK-treated HMG. Studies showed that most of those potential active ingredients have anti-inflammatory or anti-oxidative effects, such as quercetin, ([@B48], kaempferol ([@B21]; [@B52]), Luteolin ([@B4]), beta-sitosterol ([@B28]), isorhamnetin ([@B44]), delphinidin ([@B51]), troxerutin ([@B37]), cubebin ([@B5]), morin ([@B3]), linoleyl acetate ([@B38]) have anti-inflammatory effects. Compounds like quercetin ([@B47]), kaempferol ([@B24]), Luteolin ([@B59]), beta-sitosterol ([@B61]), delphinidin ([@B13]), troxerutin ([@B17]), morin ([@B32]), linoleyl acetate ([@B39]) showed anti-oxidative stress effect. Studies indicated that HMG was related to inflammatory and oxidative stress ([@B11]). Therefore, those active ingredients predicted by network pharmacology might play important role in LRK treat HMG.

Meanwhile, KEGG analysis indicated that MAPK signaling pathway contributes the most for the therapeutic effect of LRK on HMG, it might be the essential pathway for our research. Additionally, Toll-like receptor signaling pathway and TNF signaling pathway were either directly involved in inflammation or played other important roles.

Simultaneously, there were studies proved that MAPK signaling pathway is essential in regulating many cellular processes including inflammation, cell stress response, cell differentiation, cell proliferation, metabolism, motility and apoptosis ([@B1]). There were four distinct MAPK cascades including the extracellular signal-regulated kinase (p42/44 ERK)/MAPK, the p38 pathway, the c-jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK) pathway and the Big MAP kinase-1 (BMK-1) pathway ([@B7]). P38, ERK, and JNK pathway was the most important signaling pathways involving the regulation of many physiological functions of cells and playing an important role in the anthogenesis and pathophysiological process of many kinds of diseases, such as regulating the proliferations and differentiations of cells, participation in oxidative stress reaction ([@B27]). Currently, more and more researches proved that TCM have the protective effect against HMG via the possible mechanism of regulating endocrine, inflammatory and oxidative stress ([@B54]; [@B63]). And studies indicated that TCM can significantly inhibit and improve HMG in a large degree via ERK, JNK signaling pathway, as well as regulating NF-κB ([@B49]; [@B10]; [@B56]). It is well-known that NF-κB can activate the inflammatory cytokines like IL-1, TNF-α, and COX2 ([@B36]). Researches indicated that MAPK and NF-κB signaling pathway play an important role in HMG treated by TCM while NF-κB building a link among oxidative stress and inflammatory responses in HMG ([@B11]). Therefore, we verified the MAPK and NF-κB signaling pathway for further experiments.

The experimental results showed that the phosphorylation of P38, ERK, and JNK in HMG rats was significantly increased after stimulation of estrogen and progesterone. While the overexpression of p-p38, p-ERK, and p-JNK were decreased after the treatment of LRK. As the downstream of MAPK signaling pathway and an important inflammatory transcription factor, NF-κB was decreased after LRK treated. And the expression of inflammatory mediators (including IL-1, and TNF-α) and pro-inflammatory cytokines (such as COX2 and iNOS) were down-regulated after LRK treated. Those results indicated LRK could reduce inflammation in HMG.

ER and PR, as the receptor of estrogen and progestin, and studies showed PR and ERα could active the MAPK signaling pathway ([@B31]). The present study showed that LRK treatment has no effect on the expression of ERα and PR. Those results indicate that LRK might plays therapeutic effect on HMG by activating MAPK signaling pathways directly, rather than through ERα and PR to activating MAPK signaling pathways.

8-OHdG is a predominant form of free radical-induced oxidative lesions in nuclear and mitochondrial DNA. Therefore, 8-OHdG is widely used as a biomarker for oxidative stress ([@B57]; [@B2]). Nitrotyrosine (NT) is mainly formed by the reaction of superoxide radicals with NO, which is used to detect peroxynitrite ([@B18]). NT formation has been detected in a variety of systemic inflammatory diseases and is considered as a marker of NO-derived species. Estrogen can generate considerable reactive oxygen species (ROS) and lead to high level of oxidative stress ([@B11]; [@B16]). Activation of NF-κB could upregulated the expression of NO, further promote ROS and oxidative stress indexes ([@B40]). In the present study, LRK treatment significantly reduced the expression of 8-OHdG and NT. Hence, LRK may also act as an anti-oxidative agent on HMG treatment.

Our data indicated that LRK treatment protects the mammary glands from the damage of oxidative stress and inflammation via suppresses of MAPK/NF-κB signaling pathways without affecting on the expression of ERα and PR.

In this study, there were some limitations that several pathways were predicted related to the therapeutic effect of LRK on HMG via network pharmacology, however, parts of pathway were demonstrated by our experiment. Although, 19 potential active compounds were predicted by network pharmacology, and literatures reported showed anti-inflammatory and anti-oxidative effect of those ingredients, the effect of those active ingredients on HMG were still unknown. Maker clear the active ingredients is necessary for the formula research. Accordingly, in the next work of our group, we will have a comprehensive study to illuminate the active ingredients and the mechanisms of LRK against HMG.

Previous study verified the effect of MAPK inhibitor (UO126) in mammary epithelial cells (HC11 and EpH4) and breast cancer cells (MC4-L2), indicated that MAPK inhibitor could inhibit the activation of ERK signaling and suppress the proliferation, to inhibiting hyperplasia and growth ([@B15]). Our research group will further validate the effect of MAPK/NF-κB signaling pathway in LRK treat HMG by using the MAPK inhibitors to mimic the function of LRK, to proving the importance of MAPK/NF-κB signaling pathway for LRK work in HMG rat. Furthermore, we will comprehensively explicit the active ingredients of LRK by screening the active ingredients of LRK *in vitro* alternative model, and testing the active components to see whether they could achieve the similar effects as LRK treatment subsequently.

Conclusion
==========

Summarily, the present study demonstrated that there was a therapeutic effect of LRK on HMG by reducing pathological lesions in mammary gland tissue attenuating the over-activation of inflammation cytokines such as IL-1β, TNF-α, COX-2, iNOS, and suppressing the expression of 8-OHdG and NT. Furthermore, the combination of network pharmacology and experiment verification illustrated that the protect effect of LRK on HMG in rats might be associated with MAPK/NF-κB signaling pathways (Figure [8](#F8){ref-type="fig"}).

![The probable protection mechanism of LRK in HMG.](fphar-09-01318-g008){#F8}
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